IDEXX Laboratories, Inc. — Q1 2013 Form 10-Q Summary
Business Context and Reporting Period
Quarterly report for the three months ended March 31, 2013, compared with the three months ended March 31, 2012. IDEXX operates through Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other segments. LPD was newly formed by combining the prior Livestock and Poultry Diagnostics and Dairy businesses; prior-period segment information was retrospectively revised.
Key Financial Metrics
| Metric | Q1 2013 | Q1 2012 | Change |
|---|---|---|---|
| Total revenue | $332.1 million | $322.7 million | 2.9% |
| Gross profit | $184.0 million | $174.8 million | 5.3% |
| Gross margin | 55.4% | 54.2% | +120 basis points |
| Operating income | $61.2 million | $60.4 million | 1.3% |
| Operating margin | 18.4% | 18.7% | -30 basis points |
| Net income | $44.9 million | $40.7 million | 10.2% |
| Net income attributable to IDEXX stockholders | $44.9 million | $40.7 million | 10.1% |
| Diluted EPS | $0.81 | $0.72 | 12.5% |
| Cash flow from operations | $20.7 million | $15.2 million | +$5.5 million |
Revenue growth was led by CAG, which increased 3.3% to $276.9 million, and Water, which increased 5.5% to $20.7 million. LPD revenue declined 3.7% to $28.0 million. Company-wide organic revenue growth was 3.3%, excluding currency and acquisitions.
Cash and cash equivalents were $228.4 million at March 31, 2013, compared with $224.0 million at December 31, 2012. Working capital was $154.8 million, compared with $163.2 million at year-end. Accounts receivable increased to $159.0 million and inventories increased to $148.2 million.
Capital expenditures were $19.8 million, compared with $9.4 million in the prior-year quarter. Management estimated full-year 2013 capital expenditures of approximately $80 million, including headquarters expansion, information technology, manufacturing equipment, and laboratory facilities.
The company had $260.0 million outstanding under its unsecured revolving credit facility and approximately $39.0 million of remaining borrowing availability at quarter-end, after a $1.0 million letter-of-credit reduction. Long-term debt and current debt outside the facility were not material. IDEXX was in compliance with its credit-facility covenants, including the 3-to-1 consolidated leverage ratio requirement.
Material Changes Versus the Prior Comparable Period
- CAG gross margin increased to 54.2% from 52.0%, driven by pricing, favorable product mix, and reference-laboratory efficiencies.
- VetLab instruments revenue declined 23.1%, primarily because a reagent-rental program launched in late 2012 caused instrument revenue to be recognized over the rental term. VetLab consumables revenue increased 8.2%.
- Reference laboratory diagnostic and consulting services revenue increased 5.7%, primarily from price increases and higher testing volumes.
- LPD gross margin declined to 56.6% from 61.6%, reflecting unfavorable currency effects, higher manufacturing costs from lower Dairy SNAP production volumes, and lower prices for certain bovine tests.
- Operating expenses increased 7.4% to $122.8 million, causing operating margin to decline modestly despite higher gross profit.
- The effective tax rate declined to 26.2% from 31.7%. The decrease principally reflected recognition of the retroactive 2012 U.S. research and development tax credit enacted during the quarter. Without the 2012 credit, the Q1 2013 effective tax rate would have been 30.6%.
- Share repurchases increased substantially: 687,100 shares were repurchased for $63.8 million, compared with 333,000 shares for $27.6 million in Q1 2012. The company had 2.2 million shares remaining under its repurchase authorization at March 31, 2013.
- Net cash provided by financing activities was $2.3 million versus cash used of $6.6 million in the prior-year quarter, primarily because of increased borrowings and higher employee equity proceeds, partly offset by higher share repurchases.
Outlook, Commentary, Risks, and Unusual Items
- Management stated that cash on hand, operating cash flow, and available borrowings should be sufficient to fund operations, capital requirements, and strategic growth for the next twelve months and over the longer term under current conditions.
- Management was cautiously optimistic about gradual improvement in the macroeconomic environment but reported that the improvement in U.S. veterinary patient visits slowed in Q1 2013. Economic weakness continues to affect veterinary visits, diagnostic recommendations, capital purchases, Water demand, and livestock-related testing.
- Approximately 41% of revenue came from customers outside the United States and approximately 26% came from products manufactured in the United States and sold internationally in local currencies. Currency movements reduced Q1 2013 revenue by approximately $1.9 million.
- The FTC investigation into companion-animal pricing and distribution practices was resolved in February 2013 through a ten-year consent agreement. IDEXX may have exclusive distribution agreements with only two of three specified major distributors. A modified agreement with MWI became effective January 1, 2013, making MWI non-exclusive. Management does not expect the impact to be material but cannot assure that competitive effects will be fully mitigated.
- IDEXX recorded a $4.1 million loss in general and administrative expense after a freight payment and audit service provider ceased operations following employee fraud and internal-control failures. The company intends to pursue recovery, but no recovery is assured.
- The company entered into a February 2013 customer-list acquisition for $1.0 million, allocated entirely to intangible assets.
- Foreign currency contracts and interest-rate swaps are used to hedge operating and debt exposures. The company estimated that $1.6 million of net gains in accumulated other comprehensive income would be reclassified into earnings within the following twelve months, assuming exchange and interest rates remained unchanged.
- Key risks include economic weakness, foreign exchange volatility, distributor purchasing patterns and concentration, increased competition, reliance on sole or single-source suppliers, biologic manufacturing constraints, regulatory approvals, facility or system interruptions, intellectual-property claims, tax uncertainties, and credit-facility covenant compliance.
Most Important Facts for Investors to Verify
- Whether CAG organic growth, particularly consumables and reference-laboratory services, offsets continued weakness in instrument placements and slower veterinary patient-visit growth.
- The sustainability of the higher gross margin and whether increased operating expenses, manufacturing costs, and the freight-service loss pressure future operating leverage.
- The effect of the FTC consent agreement and MWI’s non-exclusive distribution status on pricing, channel economics, competitive intensity, and market share.
- Whether the lower Q1 tax rate is primarily a one-time benefit from the retroactive 2012 R&D credit and what normalized tax rate should be expected.
- Execution of the approximately $80 million 2013 capital-expenditure plan and the company’s ability to fund capital spending and substantial share repurchases while carrying $260.0 million of revolving debt.
- Potential recovery of the $4.1 million freight-service loss and the status of related claims or proceedings.
- Exposure to foreign currency movements, international economic conditions, distributor inventory levels, and supplier or manufacturing interruptions.